Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) has announced updates regarding its previously disclosed non-brokered private placement. The company will seek shareholder approval for the offering of class A multiple voting shares (MVS) at its upcoming annual general meeting on September 26, 2025. The private placement aims to raise gross proceeds of up to $600.
The offering is expected to be primarily subscribed by existing MVS holders and will include a statutory hold period of four months plus one day. The proceeds will be used for general working capital purposes. The securities being offered will not be registered under the U.S. Securities Act of 1933 and cannot be sold in the United States without registration or exemption.
["Company is raising additional working capital through private placement", "Existing MVS holders expected to participate, showing continued investor confidence"]Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a leading CDMO to manufacture an oral formulation of Lucid-MS (Lucid-21-302) for its upcoming Phase 2 clinical trial in multiple sclerosis treatment.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a characteristic feature of MS. The drug has shown promising results in animal models over the past decade, demonstrating potential in helping subjects regain walking ability. The oral formulation development represents a crucial step as the company prepares its Investigational New Drug (IND) application with the FDA.
Quantum BioPharma (NASDAQ: QNTM) announced promising results from Massachusetts General Hospital (MGH) scientists regarding a novel PET tracer [18F]3F4AP for detecting and monitoring demyelination in Multiple Sclerosis (MS) patients. The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, demonstrated the tracer's ability to detect differences across MS lesions not visible through conventional MRI.
Led by Drs. Pedro Brugarolas and Eric Klawiter at MGH and funded by NIH, the research revealed the tracer's excellent properties for brain imaging. This breakthrough could be particularly significant for monitoring the effectiveness of Quantum's investigational MS drug, Lucid-21-302, in protecting the myelin sheath in MS patients.
Quantum BioPharma (NASDAQ: QNTM) reported strong Q2 2025 results, highlighting significant financial and operational achievements. The company's total current assets increased to $10.3 million USD from $9.9 million in Q1, with total assets reaching $15.3 million USD. Notable achievements include the conversion of all debentures into equity, cryptocurrency gains exceeding $500,000 USD, and a stock price surge from $7.71 to $20.25 USD during Q2.
The company's clinical progress includes positive toxicity studies for Lucid-MS, their multiple sclerosis drug candidate, and a breakthrough PET scan imaging study with Massachusetts General Hospital. Additionally, their alcohol metabolism product unbuzzd, licensed to Unbuzzd Wellness Inc., is advancing with a $5.0 million USD Regulation D offering and potential IPO plans.
Management projects sufficient cash for operations beyond March 2027, with operating expenses at $4.9 million USD in Q2, up from $3.4 million in Q1.
Quantum BioPharma (NASDAQ: QNTM) has announced positive results from its Phase 1 Multiple Ascending Dose (MAD) clinical trial for Lucid-MS, their experimental multiple sclerosis drug. The Clinical Study Report (CSR) confirms that Lucid-MS demonstrated safety and tolerability in healthy participants with consecutive daily dosing.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a characteristic feature of multiple sclerosis. The successful completion of this trial and CSR marks a crucial milestone, enabling the company to proceed with its Investigational New Drug (IND) application to the FDA and advance toward efficacy trials in MS patients.
Quantum BioPharma (NASDAQ: QNTM) has filed a memorandum of law opposing CIBC World Markets and RBC Dominion Securities' joint motion to dismiss in the Southern District of New York. The lawsuit alleges that the defendants engaged in market manipulation through "spoofing" between January 2020 and August 2024, seeking damages exceeding $700 million USD.
The company claims its stock traded above $460 USD per share in January 2020 with a market cap approaching $1 billion before being artificially depressed. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis, eliminating material financial pressure on Quantum. The company suggests other banks may be involved but will refrain from naming them until gathering more conclusive evidence.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a Regulation D 506(c) offering to raise up to $5.0 million. The capital raise will fund growth initiatives and establish a path toward a potential IPO, without diluting Quantum BioPharma shareholders.
Quantum BioPharma maintains a 25% ownership stake in Unbuzzd through an anti-dilution provision until Unbuzzd reaches a $1 billion valuation. Unbuzzd has partnered with MZ Digital and Dealmaker for the capital raise campaign, accepting both traditional and cryptocurrency payments through ALT5 Pay's platform.
Unbuzzd is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The company produces unbuzzd™, a functional beverage designed to accelerate alcohol metabolism and reduce hangover symptoms.
Quantum BioPharma (NASDAQ: QNTM) has announced a strategic investment in GameStop Corp. (NYSE: GME), purchasing 2,000 shares. This move is part of the company's broader strategy to combat market corruption and enhance shareholder value. The company has recently appointed anti-market manipulation advocates including Kevin Malone as Board Advisor and Terry Lynch as Director.
The company is pursuing legal action against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD for alleged stock manipulation. Additionally, Quantum completed a debt settlement of US$40,000 through the issuance of Class B shares. Malone Wealth Ventures, LLC, which owns approximately 21.8% of Quantum's Class B shares, received 30,000 shares and 60,000 RSUs as consulting compensation.
Quantum BioPharma (NASDAQ: QNTM) has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program. The drug represents a first-in-class treatment for multiple sclerosis, specifically targeting demyelination.
The ILAP program is designed to accelerate the development and approval process of innovative medicines through collaboration between medicine developers, the MHRA, health assessment bodies, NHS, and patients. This submission marks the first step in potentially fast-tracking the drug's development and approval process in the UK.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a $5 million Regulation D 506(c) capital raise to fund growth and prepare for a potential IPO. The company has engaged MZ Digital for marketing and Dealmaker as the crowdfunding platform.
Unbuzzd produces a scientifically-proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The funds will support direct-to-consumer, distributor, and retail expansion plans.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
